[Update on HPV-associated head and neck cancer-highlights of the 2018 ASCO Annual Meeting].

[Update on HPV-associated head and neck cancer-highlights of the 2018 ASCO Annual Meeting]. HNO. 2018 Oct 22;: Authors: Tribius S, Würdemann N, Laban S, Sharma SJ, Wagner S, Hoffmann TK, Wittekindt C, Klussmann JP Abstract Rising incidence rates in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) and a significantly improved prognosis have brought this entity into scientific focus. At this year's American Society of Clinical Oncology (ASCO) Annual Meeting, 291 studies with the keyword "HPV" were presented, the majority of which were in head and neck cancer. Due to high rates of late toxicities after conventional therapy, de-intensified treatment concepts are being increasingly discussed, although data from prospective phase III studies were not presented. Retrospective data on the latest TNM staging (downstaging in many HPV-associated patients) and other risk stratification systems were presented. HPV diagnostics based solely on p16 immunohistochemistry were discussed. Many groups presented work on the HPV association and its prognostic relevance not only in oropharyngeal carcinoma, but also in oral cavity, hypopharyngeal, and locally advanced laryngeal squamous cell carcinoma. New prognostic biomarkers such as methylation signatures appear to be promising. New data suggest equal survival rates in HPV-associated stage I OPSCC treated with surgery alone in comparison to patients who received adj...
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research